Moscow, 10 December, 2007
EMD Serono, Inc entered license agreement with Quantum Pharmaceuticals to get an access to Quantum Pharmaceuticals’ small molecule hit identification computational platform and apply it in in-house research.
The Quantum Pharmaceuticals’ industry leading computational drug design technologies is based on applying quantum, molecular and statistical physics in molecular modeling and was successfully applied in different drug discovery projects. The initial term of the agreement is one year. The financial terms of the agreement were not disclosed.
Quantum Pharmaceuticals is a drug discovery company based in Moscow, Russia specializing in small molecule screening and design through the use of its proprietary technology platform.
EMD Serono, Inc. and Merck Serono S.A. are affiliates of Merck KGaA, Darmstadt, Germany, with over 16,000 employees worldwide and a strong presence on all continents.
No comments:
Post a Comment